Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, K. B. Nolop, Peter Hirth et al.|Nature|2010Cited by 1.8k
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trialWilliam D. Tap, Andrew J. Wagner, Sebastian Bauer et al.|The Lancet|2019Cited by 472